Akebia Therapeutics, Inc. (AKBA)
NASDAQ·Healthcare·Biotechnology
$1.43
+0.35%
Mkt Cap $383.07M
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 26, 2026 | $46.09M | $57.62M | +25.01% | -$0.03 | -$0.05 | -66.67% | — | — |
| Q4 2025 Nov 10, 2025 | $48.37M | $58.77M | +21.49% | -$0.06 | $0.00 | +103.28% | — | — |
| Q3 2025 Aug 7, 2025 | $47.89M | $62.47M | +30.45% | -$0.02 | $0.00 | +104.55% | — | — |
| Q2 2025 May 8, 2025 | $50.80M | $57.34M | +12.87% | -$0.03 | $0.03 | +200.00% | — | — |
| Q1 2025 Mar 13, 2025 | $37.41M | $46.50M | +24.28% | -$0.05 | -$0.10 | -100.00% | — | — |
| Q4 2024 Nov 7, 2024 | $40.91M | $37.43M | -8.51% | -$0.05 | -$0.10 | -100.00% | — | — |
| Q3 2024 Aug 8, 2024 | $49.45M | $43.65M | -11.73% | -$0.06 | -$0.04 | +33.33% | — | — |
| Q2 2024 May 9, 2024 | $49.45M | $32.61M | -34.06% | -$0.09 | -$0.09 | +0.00% | — | — |
| Q1 2024 Mar 14, 2024 | $55.39M | $56.20M | +1.46% | $0.00 | $0.00 | +100.00% | — | — |
| Q4 2023 Nov 8, 2023 | $55.54M | $42.05M | -24.30% | -$0.09 | -$0.08 | +11.11% | — | — |
| Q3 2023 Aug 25, 2023 | $59.10M | $56.38M | -4.61% | -$0.03 | -$0.06 | -140.00% | — | — |
| Q2 2023 May 8, 2023 | $46.68M | $40.13M | -14.04% | -$0.15 | -$0.14 | +6.67% | — | — |
| Q1 2023 Mar 9, 2023 | $47.40M | $55.18M | +16.41% | -$0.14 | -$0.04 | +71.43% | — | — |
| Q4 2022 Nov 3, 2022 | $48.88M | $48.96M | +0.17% | -$0.15 | -$0.28 | -86.67% | — | — |
| Q3 2022 Aug 4, 2022 | $53.03M | $126.76M | +139.03% | -$0.31 | $0.23 | +174.19% | — | — |
| Q2 2022 May 9, 2022 | $44.27M | $61.70M | +39.37% | -$0.27 | -$0.35 | -29.63% | — | — |
| Q1 2022 Mar 1, 2022 | $51.77M | $59.60M | +15.13% | -$0.33 | -$0.40 | -21.21% | — | — |
| Q4 2021 Nov 4, 2021 | $47.31M | $48.76M | +3.06% | -$0.32 | -$0.34 | -6.25% | — | — |
| Q3 2021 Aug 5, 2021 | $39.29M | $52.91M | +34.68% | -$0.30 | -$0.51 | -70.00% | — | — |
| Q2 2021 May 10, 2021 | $42.84M | $52.30M | +22.09% | -$0.33 | -$0.45 | -36.36% | — | — |